Patient with recurrent paratesticular malignant mesothelioma and multiple primary neoplasms

Paratesticular malignant mesothelioma (MM) is a rare tumor frequently associated with asbestos exposure. Therefore, we present an even rarer case of a 78-year-old male patient diagnosed with multiple primary neoplasms, including prostate cancer, lung cancer, paratesticular MM, and upper tract urothelial carcinoma. The patient initially presented with a painless testicular mass and had a notable medical history of prostate and lung cancers. Following physical examination and an ultrasound evaluation, he underwent radical right inguinal orchiectomy, which revealed paratesticular MM. The patient’s lung cancer recurrence and subsequent treatment coincided with periods of no MM recurrence. However, after the lung cancer treatment, the MM recurred multiple times within short intervals. This unique case indicates that systemic treatments for lung cancer, specifically cisplatin-based chemotherapy and atezolizumab immunotherapy, might also have an anti-tumor effect on paratesticular MM. Although MM combined with multiple primary neoplasms is challenging to treat and frequently recurs, treatments for other malignancies, as evidenced in this case, may have suppressive effects on the recurrence and metastasis of MM.

Malignant mesothelioma; Multiple primary neoplasm; Testicular tumors

[1] Park YJ, Kong HJ, Jang HC, Shin HS, Oh HK, Park JS. Malignant mesothelioma of the spermatic cord. Korean Journal of Urology. 2011; 52: 225–229.

[2] Bianchi C, Giarelli L, Grandi G, Brollo A, Ramani L, Zuch C. Latency periods in asbestos-related mesothelioma of the pleura. European Journal of Cancer Prevention. 1997: 6: 162–166.

[3] Howel D, Gibbs A, Arblaster L, Swinburne L, Schweiger M, Renvoize E, et al. Mineral fibre analysis and routes of exposure to asbestos in the development of mesothelioma in an English region. Occupational and Environmental Medicine. 1999; 56: 51–58.

[4] Vogt A, Schmid S, Heinimann K, Frick H, Herrmann C, Cerny T, et al. Multiple primary tumours: challenges and approaches, a review. ESMO Open. 2017; 2: e000172.

[5] Bass L, Hegeman TW. Multiple primary cancers including mesothelioma of the tunica vaginalis: case report and literature review with primary care focus. Journal of Osteopathic Medicine. 2011; 111: 483–486.

[6] Liu G, Kang S, Wang X, Shang F. Cost-effectiveness analysis of atezolizumab versus chemotherapy as first-line treatment for metastatic non-small-cell lung cancer with different PD-L1 expression status. Frontiers in Oncology. 2021; 11: 669195.

[7] Robinson BW, Musk AW, Lake RA. Malignant mesothelioma. The Lancet. 2005; 366: 397–408.

[8] Plas E, Riedl CR, Pflüger H. Malignant mesothelioma of the tunica vaginalis testis: review of the literature and assessment of prognostic parameters. Cancer. 1998; 83: 2437–2446.

[9] Roggl VL, Green CL, Liu B, Carney JM, Glass CH, Pavlisko EN. Chronological trends in the causation of malignant mesothelioma: fiber burden analysis of 619 cases over four decades. Environmental Research. 2023; 230: 114530.

[10] Repo P, Staskiewicz A, Sutinen E, Rönty M, Tero T. Kivelä, Myllärniemi M, et al. BAP1 germline variants in Finnish patients with malignant mesothelioma. Lung Cancer. 2022; 165: 102–107.

[11] Sahu RK, Ruhi S, Jeppu AK, Al-Goshae HA, Syed A, Nagdev S, et al. Malignant mesothelioma tumours: molecular pathogenesis, diagnosis, and therapies accompanying clinical studies. Frontiers in Oncology. 2023; 13: 1204722.

[12] de Sá Barrêto Callou Peixoto M, Bernardo Soares MK, Libânio BB, Albuquerque KS, Bacchi CE. Malignant mesothelioma of the tunica vaginalis testis: a rare cause of hydrocele. Urology Case Reports. 2022; 43: 102048.

[13] Karabacakoğlu B, Kısa E, Özbilen MH, Karademir B, Yardım S, Çelik O, et al. Malignant mesothelioma of tunica vaginalis: two extremely rare case reports. Urologia. 2023; 90: 422–425.

[14] Moore AJ, Parker RJ, Wiggins J. Malignant mesothelioma. Orphanet Journal of Rare Diseases. 2008; 3: 1–11.

[15] Bisceglia M, Dor DB, Carosi I, Vairo M, Pasquinelli G. Paratesticular mesothelioma. Report of a case with comprehensive review of literature. Advances in Anatomic Pathology. 2010; 17: 53–70.

[16] de Gooijer CJ, van der Noort V, Stigt JA, Baas P, Biesma B, Cornelissen R, et al. Switch-maintenance gemcitabine after first-line chemotherapy in patients with malignant mesothelioma (NVALT19): an investigator-initiated, randomised, open-label, phase 2 trial. The Lancet Respiratory Medicine. 2021; 9: 585–592.

[17] Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. Journal of Clinical Oncology. 2023; 41: 2125–2133.

[18] Assié JB, Crépin F, Grolleau E, Canellas A, Geier M, Grébert-Manuardi A, et al. Immune-checkpoint inhibitors for malignant pleural mesothelioma: a French, multicenter, retrospective real-world study. Cancers. 2022; 14: 1498.

[19] Hu ZI, Ghafoor A, Sengupta M, Hassan R. Malignant mesothelioma: advances in immune checkpoint inhibitor and mesothelin-targeted therapies. Cancer. 2021; 127: 1010–1020.

[20] Metro G, Signorelli D, Pizzutilo EG, Giannetta L, Cerea G, Garaffa M, et al. Immune checkpoint inhibitors for unresectable malignant pleural mesothelioma. Human Vaccines & Immunotherapeutics. 2021; 17: 2972–2980.

[21] Carbone M, Pass HI, Ak G, Alexander Jr HR, Baas P, Baumann F, et al. Medical and surgical care of patients with mesothelioma and their relatives carrying germline BAP1 mutations. Journal of Thoracic Oncology. 2022; 17: 873–889.